Recent interest in the CYP26 subfamily has focused on pharmacological manipulation of endogenous retinoids in the treatment of a number of diseases, particularly cancer (Bruno and Njar, 2007; Thatcher et al., 2011). This evidence concerns the gene CYP26A1 and cancer.